Cyrus Biotechnology
PrivateLast Round
Seed Round
Jul 1, 2025
Total Funding Raised
$27.15M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cyrus Biotechnology operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in September 2022.
Cyrus Biotechnology is a biotechnology company that develops AI-driven protein engineering technologies to create novel protein therapeutics for autoimmune diseases and other challenging drug targets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Vertical SaaS
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cyrus Biotechnology Comparables
Compare Cyrus Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanome | 84% | |
| Protabit | 83% | |
| Scala Biodesign | 83% |
For institutional investors. Book with your work email.
Cyrus Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jul 1, 2025 | ||||
| Early Funding | Oct 29, 2024 | ||||
| Grant | Sep 15, 2022 | ||||
| Series B | Dec 6, 2021 | ||||
| Series A | Jul 27, 2017 | ||||
Early Funding | Feb 13, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cyrus Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| iSelect Fund | Series B |
| National Institute of Allergy and Infectious Diseases | Grant |
| The Yard Ventures | Series B |
| OrbiMed | Series A, Series B |
| Washington Research Foundation Capital | Series A, Series B |
| SpringRock Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased from 0 to 7, representing 41% of headcount.
- Jul 1, 2025
$1.48M raised in Seed Round.
For institutional investors. Book with your work email.
Cyrus Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cyrus Biotechnology's valuation, stock price, and market status.
Is Cyrus Biotechnology a public or private company?
Cyrus Biotechnology is a private company.
What is the current stock price of Cyrus Biotechnology?
Cyrus Biotechnology is a private company, so its shares have no public market price. Caplight tracks Cyrus Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cyrus Biotechnology worth (valuation)?
Valuation information for Cyrus Biotechnology is not publicly available.
Can I buy Cyrus Biotechnology stock?
Cyrus Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cyrus Biotechnology's last funding round?
Cyrus Biotechnology's most recent funding round was Seed Round on July 1, 2025.
Who are the main investors in Cyrus Biotechnology?
Key investors in Cyrus Biotechnology include OrbiMed, Trinity Ventures.
Will Cyrus Biotechnology IPO soon?
No public IPO plans have been announced for Cyrus Biotechnology.
How can I track Cyrus Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Cyrus Biotechnology's shares on secondary markets.